Sustained Release Oral Formulation for Parkinson's Disease

KB
Overseen ByKhalaf Bushara, MD, FRCP
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: University of Minnesota
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

LD/CD (medications to treat Parkinson's disease) will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. The combination of CD/LD in the inner sachet varies from that in the outer sachet. This allows for sequential release of CD and then LD to mimic a CD pretreatment method which is known to increase LD absorption and prolong its half-life.

Who Is on the Research Team?

KB

Khalaf Bushara, MD, FRCP

Principal Investigator

University of Minnesota

Are You a Good Fit for This Trial?

This trial is for people diagnosed with Parkinson's disease as well as healthy volunteers. Participants should be able to use oral medications and not have any conditions that would interfere with the study or its results.

Inclusion Criteria

I am a healthy adult man or woman.
Willingness and ability to complete study procedures
I am between 18 and 65 years old.

Exclusion Criteria

I have a medical condition that requires me to take medication regularly.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive a single dose of CD/LD using a novel delivery method for pharmacokinetic analysis

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and pharmacokinetic outcomes after administration

8 hours
Continuous monitoring during the visit

What Are the Treatments Tested in This Trial?

Trial Overview

The study tests three new oral formulations (A, B, and C) of Parkinson’s medications (CD/LD) using special sachets placed between the cheek and gum. These provide a steady release of medicine to improve absorption and effects compared to standard treatments.

How Is the Trial Designed?

3

Treatment groups

Active Control

Group I: Formulation AActive Control1 Intervention
Group II: Formulation CActive Control1 Intervention
Group III: Formulation BActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Minnesota

Lead Sponsor

Trials
1,459
Recruited
1,623,000+